|
|
|
| Risk factors for posttransplant diabetes in patients with hepatocellular carcinoma |
| Yi-Yun Feng a , Ming-Zhi Xu b , c , ∗ |
a Zhejiang Chinese Medical University, Hangzhou 310053, China
b Department of General Medicine, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China
c Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University, Shulan International Medical College, Hangzhou 310015, China
∗ Corresponding author at: Department of General Medicine, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China.
E-mail address: xumz@zjcc.org.cn (M.-Z. Xu). |
|
|
|
|
Abstract Hepatocellular carcinoma (HCC) is one of the most common cause of cancer death worldwide, and in China, primary HCC ranks 4th for incidence and 2nd for mortality among all cancers [1]. Traditionally, the gold standard treatment for HCC is surgical resection, but most patients are not fit due to the advanced disease. In the 1980s, liver transplantation emerged as the treatment of choice for end-stage liver disease and also became an option for HCC patients [2]. But elevated blood glucose is a common complication after liver transplantation, affecting approximately 20%-40% of liver recipients [3]. Posttransplant diabetes mellitus (PTDM) refers to newly diagnosed diabetes mellitus (DM) after transplantation, regardless of timing or presence but undetected before transplantation [4]. In addition to all well-known complications of DM, PTDM is associated with reduced graft function, increased risk of graft failure, acute kidney injury, and increased cardiovascular risk and mortality in liver recipients [5,6]. Therefore, identifying highrisk patients and taking steps to limit the development of PTDM may improve the long-term prognosis of patients [7] . This study aimed to explore the risk factors influencing the development of PTDM after liver transplantation in HCC patients, to provide interventions for different populations before and after surgical treatment, to prevent postoperative blood glucose elevation and to improve clinical outcomes.
|
|
|
|
|
|
|
|
|
2023, Vol. 22 
